Such a test could offer prognostic value to clinicians who are unsure whether to treat their newly diagnosed patients with surgery alone, he said.
"This protein profile might be used to identify groups of patients who, independent of stage, should be offered adjuvant chemotherapy, and groups of patients who should not be offered chemotherapy," Nielsen said. "Such possible patient differentiation should, of course, be confirmed in prospective studies."
Such a study is currently underway in Denmark and other Scandinavian countries, he said. Up to 1,500 patients will be enrolled and blood samples will be collected periodically, such as before and after every treatment. The four protein markers will then be validated for disease stage, primary and secondary treatment, recurrence, and survival, and may prove to be predictive of response to individual therapies, as well as survival, Nielsen said.
The protein markers included in the test - TIMP-1, PAI-1, MASP-2, and CRP - are related to tissue remodeling, angiogenesis, and inflammation. The test uses antibodies that specifically bind to the proteins, and can analyze the actual concentration of these proteins.
MicroRNA Signature for the Human Colonic Crypt Base Region is Predictive of Colon Cancer: Abstract No. LB-6
Most researchers use gene or protein "chips" to define cancer processes, but researchers at Thomas Jefferson University in Philadelphia took a novel approach using a micro-RNA (miRNA) chip to help them understand how colon cancer develops. They found a distinct "signature" in the expression of miRNAs that predicts colon cancer.
Scientists have only recently discovered that miRNAs, which are tiny snippets of single-stranded RNA, can regulate the expression of genes, and thus regulate protein synthesis that affects cellular p
Source:American Association for Cancer Research